


Status: Currently Official on 14-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-89BFD0AE-CE43-4C90-A778-105FA8955285\_2\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M26730\\_02\\_01](https://doi.org/10.31003/USPNF_M26730_02_01)  
 DOI Ref: em6xc

© 2025 USPC  
 Do not distribute

## Dinoprost Tromethamine



$C_{20}H_{34}O_5 \cdot C_4H_{11}NO_3$  475.62

Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9α,11α,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1).

(E,Z)-(1R,2R,3R,5S)-7-[3,5-Dihydroxy-2-[(3S)-(3-hydroxy-1-octenyl)]cyclopentyl]-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1).

Prostaglandin F<sub>2a</sub> tromethamine CAS RN®: 38562-01-5; UNII: CT6BBQ5A68.

» Dinoprost Tromethamine contains not less than 95.0 percent and not more than 105.0 percent of  $C_{20}H_{34}O_5 \cdot C_4H_{11}NO_3$ , calculated on the dried basis. [CAUTION—Great care should be taken to prevent inhaling particles of Dinoprost Tromethamine and exposing the skin to it.]

**Packaging and storage**—Preserve in tight containers.

**USP REFERENCE STANDARDS (11)**—

[USP Dinoprost Tromethamine RS](#)

**Change to read:**

**IDENTIFICATION**, ▲ [Spectroscopic Identification Tests \(197\)](#), [Infrared Spectroscopy: 197M](#). ▲ (CN 1-May-2020)

**SPECIFIC ROTATION (781S)**: between +19° and +26°.

*Test solution*: 20 mg per mL, in alcohol.

**LOSS ON DRYING (731)**—Dry it in vacuum at room temperature and at a pressure not exceeding 5 mm of mercury for 16 hours: it loses not more than 1.0% of its weight.

**RESIDUE ON IGNITION (281)**: not more than 0.5%.

**Chromatographic purity**—[NOTE—Prepare solutions immediately prior to use.]

*Mobile phase*—Proceed as directed in the Assay.

*Standard stock solution*—Prepare as directed for *Standard preparation* in the Assay.

*Standard solution*—Transfer 1.0 mL of the *Standard stock solution* to a 50-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

*Test solution*—Prepare as directed for the Assay preparation.

*Chromatographic system*—Proceed as directed in the Assay. Chromatograph the *Test solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between dinoprost tromethamine and any other adjacent peak is not less than 1.0.

*Procedure*—Separately inject equal volumes (about 10 µL) of the *Standard solution* and the *Test solution* into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the percentage of each impurity in the portion of Dinoprost Tromethamine taken by the formula:

$$2.5(C/W)F(r_i/r_s)$$

in which *C* is the concentration, in µg per mL, of [USP Dinoprost Tromethamine RS](#) in the *Standard solution*; *W* is the weight, in mg, of Dinoprost Tromethamine taken to prepare the *Test solution*; *F* is the relative response factor and is equal to 0.25 for any peak at a relative retention time of about 0.30, 1.7 for any peak at a relative retention time of about 1.15, and 1.0 for any other peak; *r<sub>i</sub>* is the peak response of each impurity obtained from the *Test solution*; and *r<sub>s</sub>* is the peak response of dinoprost tromethamine obtained from the *Standard solution*: not more than 2.0% of any impurity having a relative retention time of about 0.94 is found; not more than 1.5% of any impurity having a relative retention time of about 0.84 is found; not more than 0.5% of any other impurity is found; and not more than 2.0% of all other impurities is found.

**Assay**—[NOTE—Prepare solutions immediately prior to use.]

*Mobile phase*—Prepare a filtered and degassed mixture of water, acetonitrile, and phosphoric acid (750:250:1). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Standard preparation*—Dissolve an accurately weighed quantity of [USP Dinoprost Tromethamine RS](#) in *Mobile phase*, and dilute quantitatively, and stepwise if necessary, with *Mobile phase* to obtain a solution having a known concentration of about 1.0 mg per mL.

*Assay preparation*—Transfer about 25.0 mg of Dinoprost Tromethamine, accurately weighed, to a 25-mL volumetric flask, dissolve in and dilute with *Mobile phase* to volume, and mix.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 200-nm detector and a 3.9-mm × 15-cm column that contains packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the column efficiency is not less than 6000 theoretical plates, and the relative standard deviation for replicate injections is not more than 2.0%.

*Procedure*—Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C<sub>20</sub>H<sub>34</sub>O<sub>5</sub> · C<sub>4</sub>H<sub>11</sub>NO<sub>3</sub> in the portion of Dinoprost Tromethamine taken by the formula:

$$25C(r_u/r_s)$$

in which C is the concentration, in mg per mL, of [USP Dinoprost Tromethamine RS](#) in the *Standard preparation*; and *r<sub>u</sub>* and *r<sub>s</sub>* are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DINOPROST TROMETHAMINE	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 28(4)

**Current DocID:** [GUID-89BFD0AE-CE43-4C90-A778-105FA8955285\\_2\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M26730\\_02\\_01](https://doi.org/10.31003/USPNF_M26730_02_01)

**DOI ref:** [em6xc](#)